Lifeboat Foundation: Safeguarding Humanity
Toggle light / dark theme

Blog – Page 2750

In the phase 3 GLOW study, ibrutinib plus venetoclax significantly improved progression-free survival and other outcomes in patients with chronic lymphocytic leukemia, across most genomic subgroups.

Patients treated with fixed-duration ibrutinib (Imbruvica) plus venetoclax (Venclexta) achieved higher undetectable minimal residual disease (uMRD), progression-free survival (PFS), and overall survival (OS) rates compared with chlorambucil plus obinutuzumab (Gazyva) across most genomic subgroups of chronic lymphocytic leukemia (CLL).1.

Findings come from the phase 3 GLOW study (NCT03462719) in which data were presented at the 11th Annual Meeting of the Society of Hematologic Oncology (SOHO 2023). Patients treated with ibrutinib and venetoclax achieved a higher uMRD rate at 3 months (54.7%) after the end of treatment compared with patients treated with obinutuzumab and chlorambucil (39.0%), except patients with trisomy-12, IGLL5 mutation, and mutated immunoglobulin heavy-chain variable (mIGHV).

Read more | >

“Welcome to another exciting episode of AI News! Our top story today is the release of ChatGPT’s DALL-E 3, an AI system that is revolutionizing image generation. We’ll also be discussing Google’s BARD and its recent upgrade, as well as the impressive $40M funding received by Legit Security to protect AI applications from cyber threats. Stay tuned for these stories and more in this episode of AI News. Don’t forget to subscribe and hit the bell icon so you never miss an update on the latest developments in Artificial Intelligence!”

Read more | >

The economic downturn is already a devastating blow to job seekers everywhere. Now scammers are taking advantage of the situation by ramping up their methods of swindling people.

Job scamming is a threat to job seekers all over the world. For example, the Better Business Bureau (BBB) reported an increase in job scam complaints in the United States and Canada in the past several years. Singapore job seekers lost $660 million SGD ($495 million USD) in 2022 alone. And in the UK, 10,000 people were approached on LinkedIn and Facebook by “foreign spies and malicious actors” to steal information.

Phishing attacks and malware are the primary methods of scamming job seekers, according to a February Trellix report. Scammers create fake websites, often employing typosquatting. A fake site uses a real name like Indeed that’s slightly misspelled (such as “Indeeed”) or extends the URL in hopes the job seeker will not notice the base domain name. These sites appear legitimate but are used to steal passwords and financial information.

Read more | >

In a new study in mice, a team of researchers from UCLA, the Swiss Federal Institute of Technology, and Harvard University have uncovered a crucial component for restoring functional activity after spinal cord injury. The neuroscientists have shown that re-growing specific neurons back to their natural target regions led to recovery, while random regrowth was not effective.

In a 2018 study published in Nature, the team identified a treatment approach that triggers axons —the tiny fibers that link and enable them to communicate—to regrow after spinal cord in rodents. But even as that approach successfully led to the of across severe spinal cord lesions, achieving functional recovery remained a significant challenge.

In a new study, published in Science, the team aimed to determine whether directing the regeneration of axons from specific neuronal subpopulations to their natural target regions could lead to meaningful functional restoration after spinal cord injury in . They first used advanced genetic analysis to identify nerve cell groups that enable walking improvement after a partial spinal cord injury.

Read more | >

Generative artificial intelligence – the kind of AI behind the hugely popular ChatGPT application – already is disrupting the healthcare industry. C-suite executives and other health IT leaders at provider organizations need to know much to keep up and what to be wary of.

Venky Anant is a partner at research and consulting firm McKinsey Digital. He is our guest on this week’s podcast. He has vast expertise in AI and knows well its disruptive potential.

Read more | >